Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

main

Inflation Reduction Act and Medicare Pricing for Drugs and Biologics

Inflation Reduction Act & Medicare Pricing for Drugs and Biologics | Goodwin

Inflation Reduction Act & Medicare Pricing for Drugs and Biologics

Updates & Analysis

Lead Editor

Matt Wetzel

Contributing Editor

Alexandra Lu

Related Content

A Look Ahead in Life Sciences: What We Are Tracking in Q3 2023 and Beyond

Life Sciences Regulatory & Compliance

Late Stage Drug Development

Patent Litigation

Inflation Reduction Act & Medicare Pricing for Drugs and Biologics

Updates & Analysis

Inflation Reduction Act: An Overview

Inflation Reduction Act Infographic

The Inflation Reduction Act: Summer 2023 Updates

Inflation Reduction Act: Threats and Opportunities for UK Life Sciences

Initial Lawsuits Claim IRA’s Compelled Drug-Price Negotiation Is Broad Break With Rule Of Law

Inflation Reduction Act: Washington Legal Foundation Update (October 2023)